title: Concurrent mental health therapy among medicaid-enrolled youths starting antipsychotic medications.
abstract: OBJECTIVE
  The use of antipsychotic medications among children and adolescents has increased substantially in recent years, predominantly in disorders for which effective psychosocial interventions exist. The authors of this study examined the extent to which youths being prescribed antipsychotic medications were receiving concurrent mental health therapy.
  
  
  METHODS
  Using administrative data, the authors identified 6,110 Medicaid-enrolled youths starting antipsychotic medications from November 1, 2006, through October 31, 2009, and identified youths who had received any concurrent mental health therapy. Multivariate regression models were used to examine the relationship between concurrent therapy and sociodemographic and clinical variables.
  
  
  RESULTS
  Sixty-eight percent (N=4,155) of youths starting antipsychotic medications received concurrent therapy. Multivariate regression findings are that concurrent therapy was more common with younger children, recently hospitalized youths, children from urban communities, youths from racial-ethnic minority groups, children with an antipsychotic-indicated diagnosis, and youths eligible for Medicaid because of family income.
  
  
  CONCLUSIONS
  The finding that 68% of youths starting antipsychotic medications received concurrent therapy suggests that for a majority of children, these medications complemented rather than substituted for nonpharmacologic interventions. However, with almost one-third of youths not receiving concurrent therapy, a better understanding of the factors contributing to the lack of concurrent therapy for youths starting antipsychotic medications is needed. Children and families should be aware of and have access to effective psychosocial treatments for disorders such as attention-deficit hyperactivity disorder and depression that are common among children receiving antipsychotic medications.
authors.affiliation: Department of Psychiatry, University of Pittsburgh, USA.
authors.forename: Emily
authors.initials: E
authors.lastname: Harris
authors.forename: Mark
authors.initials: M
authors.lastname: Sorbero
authors.forename: Jane N
authors.initials: JN
authors.lastname: Kogan
authors.forename: James
authors.initials: J
authors.lastname: Schuster
authors.forename: Bradley D
authors.initials: BD
authors.lastname: Stein
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D004363:Drug Utilization / Q000706:statistics & numerical data* / Q000639:trends; D005006:Ethnicity / Q000523:psychology / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008484:Medicaid / Q000706:statistics & numerical data*; D001523:Mental Disorders / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy*; D015999:Multivariate Analysis; D056687:Off-Label Use / Q000706:statistics & numerical data; D011618:Psychotic Disorders / Q000453:epidemiology; D012424:Rural Population / Q000706:statistics & numerical data; D012959:Socioeconomic Factors; D014481:United States / Q000453:epidemiology; D014505:Urban Population / Q000706:statistics & numerical data
chemical_list: D014150:Antipsychotic Agents